ImmunoGen, Inc. (NASDAQ:IMGN) reported Q2 2017 earnings this Morning, coming in at ($0.10) per share, beating Wall Street’s estimates of ($0.17) per Share. Revenue for the quarter came in at $39.02 million beating analyst estimates of $30.59 million
Analyst Coverage For ImmunoGen, Inc. (NASDAQ:IMGN)
These are 1 Sell Rating, 3 Hold Ratings, 5 Buy Ratings .
The current consensus rating for ImmunoGen, Inc. (NASDAQ:IMGN) is Hold (Score: 2.44) with a consensus target price of $6.61 , a potential (8.61% upside)Recent Insider Trading for ImmunoGen, Inc. (NASDAQ:IMGN)
- On 12/15/2016 Mark Alan Goldberg, Director, bought 20,000 with an average share price of $1.80 per share and the total transaction amounting to $36,000.00.
- On 11/8/2016 Mark J Enyedy, CEO, bought 25,000 with an average share price of $1.83 per share and the total transaction amounting to $45,750.00.
- On 11/2/2016 Craig Barrows, Insider, bought 10,000 with an average share price of $1.71 per share and the total transaction amounting to $17,100.00.
- On 11/2/2016 Richard J Gregory, VP, bought 16,600 with an average share price of $1.78 per share and the total transaction amounting to $29,548.00.
- On 2/1/2016 John Lambert, EVP, sold 3,889 with an average share price of $8.22 per share and the total transaction amounting to $31,967.58.
- On 1/8/2016 Richard J Gregory, VP, sold 2,369 with an average share price of $11.10 per share and the total transaction amounting to $26,295.90.
Recent Trading for ImmunoGen, Inc. (NASDAQ:IMGN) Shares of ImmunoGen, Inc. closed the previous trading session at 6.65 up +0.56 9.20% with 3,846,610 shares trading hands.